Velizy, August 25, 2009 – CARMAT SAS, a medical device company and EADS spin-off developing a total artificial heart (Video) for use in late-stage heart failure, today announced the election of André-Michel Ballester (Sorin S.P.A. CEO), Peter Steinmann (Former vice-President, Medtronic), and Michel Finance (acting CARMAT CEO) to its Board of Directors.
"We are delighted that André-Michel Ballester and Peter Steinmann have agreed to join CARMAT as independent board members. Both are internationally renowned senior executives in the cardiovascular medtech industry. They will help us successfully develop the most advanced total artificial heart in the world. Were are also very pleased to have CARMAT acting CEO Michel Finance join the Board”, stated Jean-Claude Cadudal, CARMAT’s Chairman.
André-Michel Ballester is a specialist in cardiovascular surgery devices and started his healthcare industry career at Travenol in the 1980s. He has since held senior management positions in the medical device and life science industries in Europe and the US. André-Michel Ballester is currently CEO of Sorin S.P.A, one of the leading provider of medical devices for cardiovacular diseases. He has an exceptional knowledge of this industry. André-Michel Ballester is a graduate of Ecole Centrale de Lille engineering school and of INSEAD business school.
Peter Steinmann is an industry expert who started his career in finances. After moving into the medical device sector, he held various senior management positions in Europe and Canada for 20 years within world-leading multinationals (including Johnson & Johnson). He most recently served as Vice-President Western Europe at Medtronic, the global leader and innovator in cardiovascular medical technology. Thanks to his multifaceted international experience, Peter Steinmann is currently acting as an independent consultant. Peter Steinmann is a graduate of Boston University.
Michel Finance is CARMAT’s acting CEO and has extensive experience of both general and financial management. After starting his career as an auditor at Price Waterhouse Coopers, he held a series of senior executive positions in the pharmaceutical and biotechnology industries (including CFO at Aventis Pasteur) over a 25-year period. Prior to joining CARMAT, Michel Finance served as Executive Vice-President at Flamel Technologies from 2005 to 2008. Michel Finance is a graduate from EM Lyon business school and has been a Board member at France Biotech (the French biotechnology association) since 2006.
New CARMAT S.A.S. Board of Directors
Jean-Claude Cadudal, Chairman
André-Michel Ballester, independent board member
Professor Alain Carpentier, Chief Scientific Officer
Michel Finance, Acting CEO
Philippe Pouletty, MD, (General Partner, TRUFFLE CAPITAL)
Peter Steinmann, independent board member
About CARMAT SAS:
Paris-based CARMAT was created in June 2008 by venture capital fund TRUFFLE CAPITAL (http://www.truffle.com), EADS (http://www.eads.com) and the Fondation Alain Carpentier, with additional funding from the French state innovation agency OSEO (http://www.oseo.fr/). The company was spun out of a 15 years collaboration between EADS and renowned cardiac surgeon Alain Carpentier using biomaterials and cutting-edge aerospace technologies for the development of a breakthrough artificial heart. CARMAT intends to market a fully implantable artificial heart that may provide renewed hope and enhanced quality of life to the hundreds of thousands of patients suffering from a massive heart attack or late-stage heart failure and for whom standard drug therapy, ventricular assistance and/or a heart transplant have failed or are not possible.
www.carmatsas.com
André-Michel Ballester is a specialist in cardiovascular surgery devices and started his healthcare industry career at Travenol in the 1980s. He has since held senior management positions in the medical device and life science industries in Europe and the US. André-Michel Ballester is currently CEO of Sorin S.P.A, one of the leading provider of medical devices for cardiovacular diseases. He has an exceptional knowledge of this industry. André-Michel Ballester is a graduate of Ecole Centrale de Lille engineering school and of INSEAD business school.
Peter Steinmann is an industry expert who started his career in finances. After moving into the medical device sector, he held various senior management positions in Europe and Canada for 20 years within world-leading multinationals (including Johnson & Johnson). He most recently served as Vice-President Western Europe at Medtronic, the global leader and innovator in cardiovascular medical technology. Thanks to his multifaceted international experience, Peter Steinmann is currently acting as an independent consultant. Peter Steinmann is a graduate of Boston University.
Michel Finance is CARMAT’s acting CEO and has extensive experience of both general and financial management. After starting his career as an auditor at Price Waterhouse Coopers, he held a series of senior executive positions in the pharmaceutical and biotechnology industries (including CFO at Aventis Pasteur) over a 25-year period. Prior to joining CARMAT, Michel Finance served as Executive Vice-President at Flamel Technologies from 2005 to 2008. Michel Finance is a graduate from EM Lyon business school and has been a Board member at France Biotech (the French biotechnology association) since 2006.
New CARMAT S.A.S. Board of Directors
Jean-Claude Cadudal, Chairman
André-Michel Ballester, independent board member
Professor Alain Carpentier, Chief Scientific Officer
Michel Finance, Acting CEO
Philippe Pouletty, MD, (General Partner, TRUFFLE CAPITAL)
Peter Steinmann, independent board member
About CARMAT SAS:
Paris-based CARMAT was created in June 2008 by venture capital fund TRUFFLE CAPITAL (http://www.truffle.com), EADS (http://www.eads.com) and the Fondation Alain Carpentier, with additional funding from the French state innovation agency OSEO (http://www.oseo.fr/). The company was spun out of a 15 years collaboration between EADS and renowned cardiac surgeon Alain Carpentier using biomaterials and cutting-edge aerospace technologies for the development of a breakthrough artificial heart. CARMAT intends to market a fully implantable artificial heart that may provide renewed hope and enhanced quality of life to the hundreds of thousands of patients suffering from a massive heart attack or late-stage heart failure and for whom standard drug therapy, ventricular assistance and/or a heart transplant have failed or are not possible.
www.carmatsas.com
